Ann: First patient dosed in Phase 1 bile tract cancer trial, page-116

Having been a holder for a while and continue to increase my exposure to this stock (while certainly being no expert on immunotherapy) I would say that this is the trial I am most excited about. Unlike the previous trial whose data update jumped the price last year, this trial has many more attributes...

Firstly, it is with higher dosage levels, which must be starting to get close to OBD???

Secondly, I believe it is not with patients that have had other lines of treatment and hence don't have a greatly reduced immune system. Which is really import when trying to establish the effectiveness of an immunotherapy drug.

And thirdly, I think it has been even more sanctioned, and hence watched, by the FDA as this particular cancer has no existing effective treatment.

I understand that bile duct cancer is a limited market, so IMU will not go on to riches just for this particular line of treatment. But of course, when it is proven to work for one type of cancer, then people are going to give it more attention and consider it for others.

So, if the study in mice is ultimately replicated in humans, then hold on to your hat. Actually, it is more of a case of pull up a chair, read the paper and have a nice bottle of wine over a very long period. This is not a rocket, it is instead a great test of patience and perseverance. But ohhhhh, what a goal.